Monopar Therapeutics financials
$80.00−4.44%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$6.6M | -$5.2M | -$6.2M | -$4.1M | -$3.2M | -$3.2M | -$11.1M | -$1.6M | -$1.8M | -$1.7M | -$1.9M | -$2.1M |
| Net income | -$5.3M | -$3.9M | -$5.2M | -$3.4M | -$2.5M | -$2.6M | -$10.9M | -$1.3M | -$1.7M | -$1.6M | -$1.8M | -$2.0M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.62 | $-0.46 | $-0.61 | $-0.48 | $-0.35 | $-0.38 | $-2.21 | $-0.37 | $-0.49 | $-0.51 | $-0.35 | $-0.69 |
| EBITDA | -$6.6M | -$5.2M | -$6.2M | -$4.1M | -$3.2M | -$3.2M | -$11.1M | -$1.6M | -$1.8M | -$1.7M | -$1.9M | -$2.1M |
| Operating cash flow | -$3.2M | -$3.5M | -$3.4M | -$2.1M | -$1.1M | -$5.7M | -$2.0M | -$1.1M | -$1.7M | -$1.7M | -$1.5M | -$1.9M |
| Free cash flow | -$3.2M | -$3.5M | -$3.4M | -$2.1M | -$1.1M | -$5.7M | -$2.0M | -$1.1M | -$1.7M | -$1.7M | -$1.5M | -$1.9M |
| Diluted shares | 8.5M | 8.5M | 8.5M | 7.1M | 7.0M | 7.0M | 4.9M | 3.5M | 3.5M | 3.2M | 5.2M | 2.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $52.8M | $52.5M | $61.8M | $127.7M | $39.5M | $39.7M |
| Short-term investments | $81.5M | $84.9M | $78.6M | $16.0M | $13.7M | $14.8M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $135.0M | $138.0M | $140.7M | $144.2M | $53.9M | $55.1M |
| Total liabilities | $4.1M | $2.6M | $2.9M | $2.6M | $1.7M | $1.5M |
| Shareholders' equity | $130.9M | $135.4M | $137.8M | $141.6M | $52.2M | $53.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology